Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors
- 1 August 2000
- journal article
- Published by Elsevier in Drug Discovery Today
- Vol. 5 (8) , 344-353
- https://doi.org/10.1016/s1359-6446(00)01534-8
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Science, medicine, and the future: Antivascular therapy: a new approach to cancer treatmentBMJ, 1999
- The Rationale and Future Potential of Angiogenesis Inhibitors in NeoplasiaDrugs, 1999
- Inhibition of malignant angiogenesisCancer Treatment Reviews, 1997
- Receptor tyrosine kinases as targets for inhibition of angiogenesisDrug Discovery Today, 1997
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Current approaches to targeting cancer using antiangiogenesis therapiesCancer Treatment Reviews, 1994
- Specificity of Vascular Endothelial Cell Growth Factor Receptor Ligand Binding DomainsBiochemical and Biophysical Research Communications, 1994
- Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.Proceedings of the National Academy of Sciences, 1993
- TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATIONThe Journal of Experimental Medicine, 1972
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971